Patients with papillary thyroid cancer generally have a good long-term prognosis; however, the benefits of adjuvant radioactive iodine therapy in patients with intermediate risk have been debated. In a new study in patients with intermediate-risk papillary thyroid cancer, 21,870 patients received the adjuvant therapy and 6,452 patients did not. After a mean follow-up of 6 years, adjuvant radioactive iodine therapy was shown to be associated with improved overall survival.
References
Ruel, E. et al. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate risk papillary thyroid cancer. J. Clin. Endocrinol. Metab. 10.1210/jc.2014-4332
Rights and permissions
About this article
Cite this article
Improving survival in patients with papillary thyroid cancer. Nat Rev Endocrinol 11, 194 (2015). https://doi.org/10.1038/nrendo.2015.21
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2015.21